Results 11 to 20 of about 1,335,305 (294)

Risk of Bacterial Infection from Proton Pump Inhibitor Use

The Korean Journal of Helicobacter and Upper Gastrointestinal Research, 2017
Currently, proton pump inhibitors are used in a wide range of patients with gastroesophageal reflux disease, peptic ulcer, and upper gastrointestinal symptoms such as dyspepsia.
Sung Soo Kim, Yunju Jo, Seun Ja Park, Jeong Seop Moon, Dong Ho Lee, Jae Jun Kim, Yong Chan Lee, Ethics and Education Committee of Korean College of Helicobacter and Upper Gastrointestinal Research   +7 more
doaj   +2 more sources

Proton Pump Inhibitor use in Hospitalized Patients: Is Overutilization Becoming a Problem?

Clinical Medicine Insights: Gastroenterology, 2012
Proton pump inhibitors (PPIs) are among the most common classes of medications prescribed. Though they were previously thought of as safe, recent literature has shown risks associated with their use including increased risk for Clostridium difficile ...
Cheryl Durand, Kristine C. Willett, Alicia R. Desilets   +2 more
doaj   +4 more sources

Antiplatelet agents and proton pump inhibitors – personalizing treatment

Pharmacogenomics and Personalized Medicine, 2010
Eugene Lin, Rajiv Padmanabhan, Majaz MoonisDepartment of Neurology, University of Massachusetts Medical School and UMass Memorial Medical Center, Worcester, Massachusetts, USAIntroduction: Antiplatelet therapy remains one of the cornerstones in the ...
Eugene Lin, Rajiv Padmanabhan, Majaz Moonis   +2 more
doaj   +1 more source

Proton pump inhibitor-induced nephrotoxicity [PDF]

, 2021
Proton pump inhibitors are widely used, and generally considered safe. In this clinical lesson two cases are presented with a strong suspicion of proton pump inhibitor induced decline of kidney function.
Dekker, F W, Klatte, D C F, Gansevoort, R T, Wiegersma, J S   +3 more
core   +4 more sources

Association between proton pump inhibitor therapy and clostridium difficile infection: a contemporary systematic review and meta-analysis. [PDF]

, 2012
Introduction Emerging epidemiological evidence suggests that proton pump inhibitor (PPI) acid-suppression therapy is associated with an increased risk of Clostridium difficile infection (CDI).
Sutton, AJ, Imad M. Tleyjeh (104252), Tannir Mohamad Al, Alex J Sutton, AlGhamdi, M, Muhammad Riaz (104236), Bin Abdulhak, AA, Ibrahim Talal, Mushabab AlGhamdi (112556), Baddour, LM, Alasmari Faisal A., A. A. Bin Abdulhak (7656569), Abed Allehibi, Talal Ibrahim (112568), Allehibi, A., Alasmari, FA, Faisal A. Alasmari (112549), F. A. Alasmari (7656575), A. R. Khan (3951662), AlGhamdi Mushabab, A. AlLehibi (7656593), Khan, AR, Al Tannir, M, Tleyjeh, IM, I. M. Tleyjeh (7656566), AlGhamdi, M., Abed AlLehibi (112573), Khan, A. R., Alex J. Sutton (112577), Garbati Musa A., L. M. Baddour (7656596), Aref A Bin Abdulhak, M. A. Garbati (7656578), M. Al Tannir (7656584), Bin Abdulhak, A. A., M. AlGhamdi (7656581), Erwin, P. J., Imad M Tleyjeh, Khan Abdur Rahman, Tleyjeh, I. M., Patricia J Erwin, T. Ibrahim (7656590), Muhammad Riaz, Abdur Rahman Khan (104234), Garbati, MA, Allehibi, A, Bin Abdulhak Aref A., Erwin, PJ, Sutton Alex J., M. Riaz (7656572), Riaz Muhammad, Musa A Garbati, Alasmari, F. A., Patricia J. Erwin (104246), Talal Ibrahim, Abdur Rahman Khan, Ibrahim, T., Mushabab AlGhamdi, A. J. Sutton (7648487), Faisal A Alasmari, Ibrahim, T, Mohamad Al Tannir (112562), Mohamad Al Tannir, Erwin Patricia J., Larry M Baddour, Baddour Larry M., Al Tannir, M., P. J. Erwin (7656587), Aref A. Bin Abdulhak (104239), Garbati, M. A., Larry M. Baddour (104249), Riaz, Muhammad, Riaz, M, Tleyjeh Imad M., Baddour, L. M., Sutton, A. J., Musa A. Garbati (104244), AlLehibi Abed   +77 more
core   +1 more source

Comparison of Proton Pump Inhibitor and Triple Therapy Regimen for Laryngospharyngeal Reflux Disease

Journal of Nepal Health Research Council, 2020
Background: Laryngopharyngeal reflux is retrograde flow of contents of the stomach to the larynx and the pharynx. The study aims to compare two regimens (proton pump inhibitor monotherapy versus triple therapy) on the outcome of Helicobactor pylori ...
Apar Pokharel, Jaya Prakash Mayya, Hari Prasad Upadhyay   +2 more
doaj   +1 more source

Proton pump inhibitors and gastroenteritis [PDF]

European Journal of Epidemiology, 2016
An association between proton pump inhibitor (PPI) therapy and bacterial gastroenteritis has been suggested as well as contradicted. The aim of this study was to examine the association between the use of PPIs and occurrence of bacterial gastroenteritis in the prospective Rotterdam Study.
Hassing, Robert-Jan, Verbon, Annelies, Visser, H, Hofman, Bert, Stricker, Bruno   +4 more
openaire   +2 more sources

Iron deficiency anemia from iron malabsorption caused by proton pump inhibitors

eJHaem, 2020
Background Iron deficiency anemia without evidence for blood loss can present a diagnostic challenge. Proton pump inhibitors have been associated with iron deficiency anemia for many years, yet the relationship between the two until recently was not ...
Michael Boxer
doaj   +1 more source

Overuse of proton pump inhibitors [PDF]

Polish Archives of Internal Medicine, 2015
Proton pump inhibitors (PPIs) are currently the most effective drugs inhibiting hydrochloric acid secretion. They have replaced histamine type 2 receptor antagonists in the majority of clinical indications, for example, functional dyspepsia, gastroesophageal reflux disease, or drug‑induced upper gastrointestinal tract injury.
Dorota, Ksiądzyna, Adam, Szeląg, Leszek, Paradowski   +2 more
openaire   +2 more sources

Proton Pump Inhibitors and CKD [PDF]

Journal of the American Society of Nephrology, 2016
Proton pump inhibitors (PPIs) are taken by millions of people around the world, often for many months or even years, and some take PPIs on a permanent basis. PPIs, which are available both by prescription and over the counter, generally have an excellent overall safety profile.
Dennis G, Moledina, Mark A, Perazella
openaire   +2 more sources